Core Insights - Viatris Inc. (NASDAQ: VTRS) is recognized as one of the 13 Best March Dividend Stocks to Buy [1] - UBS has raised its price target for Viatris from $18 to $20, maintaining a Buy rating, citing the company's achievement of Q4 cost-saving goals and positive FY26 guidance [2] - The company reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion for Q4 2025, indicating strong financial performance [3] Financial Performance - Viatris achieved total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion in Q4 2025, reflecting the overall strength of the business [3] - The company returned over $1 billion to shareholders through dividends and share repurchases during the year [4] Growth Outlook - Viatris expects to generate approximately $650 million in gross cost savings over three years, with up to $250 million reinvested into growth initiatives [5] - The company is preparing for a potential FDA reinspection of its Indore facility, implementing operational redundancies to ensure continuity and stability [5] Pipeline Progress - Five Phase III studies have delivered positive results, marking an important milestone for the company [4] - Enrollment in key programs, including cenerimod and selatogrel, is progressing and expected to be completed in 2026 [4] Strategic Initiatives - The completion of 60 regional transactions, including the acquisition of Aculys Pharma in Japan, is part of Viatris' broader strategic plan [4]

Core Insights - The article discusses the best dividend stocks to buy in March, emphasizing the importance of dividend income as a stable complement to capital appreciation during market uncertainty [1][4]. Dividend Trends - Nuveen highlights that while share buybacks have surpassed dividends in recent years, dividends have shown more consistency and are expected to grow strongly across the S&P 500 in 2026 due to solid earnings growth and improved cash flow [2][3]. - The firm anticipates that sectors such as information technology, financials, and industrials will experience the strongest dividend growth, while consumer staples, utilities, and consumer discretionary sectors are expected to see more modest growth [3]. Company-Specific Insights - eBay Inc. plans to cut approximately 800 jobs, representing about 6% of its workforce, to align staffing with strategic priorities, while also continuing to hire in critical areas [9]. - eBay's revenue rose 15% year-over-year to $3 billion in Q4, exceeding analyst expectations, despite the layoffs being the third round in three years [10][9]. - Viatris Inc. received a price target increase from UBS, which raised its recommendation to $20 from $18, citing strong Q4 performance and positive guidance for FY26 [12]. - Viatris reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion for 2025, indicating a strong business position and a path toward sustainable long-term growth starting in 2026 [13]. - The company plans to generate about $650 million in gross cost savings over three years, with a portion reinvested into growth initiatives [15].

Key Takeaways Theravance Biopharma is favored over CorMedix for its balanced risk-reward profile in 2026.TBPH benefits from Yupelri profit-sharing and a $225M Trelegy royalty sale, boosting cash runway.CorMedix expects to face slower 2026 DefenCath growth and pricing pressure amid rising competitive risks.CorMedix (CRMD) and Theravance Biopharma (TBPH) occupy a similar niche in the market as small-cap biopharmaceutical companies working to turn promising science into sustainable revenues. Both companies, ha ...

NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 3, 2026 at 11:00 AM ET. The event will feature presentations by Aaron Miller, MD (Corinne Dickinson Center for Multiple Sclerosis, Icahn School of Medicine, Mount Sinai) and Carlo S. Tornatore, ...

Core Viewpoint - Viatris Inc. (NASDAQ:VTRS) is recognized as a promising investment opportunity among cheap pharmaceutical stocks, particularly following an upgrade from UBS, which highlights the company's growth potential and efficient capital allocation [1][3]. Group 1: Company Performance and Upgrades - UBS upgraded Viatris to a Buy rating from Neutral and increased the price target from $11 to $18, reflecting stronger growth prospects [3]. - The upgrade is attributed to Viatris' new product pipeline, ongoing cost-cutting initiatives, and rising profits, which are expected to enhance shareholder value [3][10]. Group 2: Product Launches and Innovations - Viatris launched Inpefa (sotagliflozin) in the UAE, marking the first market outside the U.S. for this treatment, with plans for additional global launches [4][5]. - Inpefa is a first-in-class dual SGLT1/2 inhibitor aimed at reducing the risk of cardiovascular death and hospitalizations in patients with heart failure, including those with type 2 diabetes or chronic renal illness [5]. - The company has submitted regulatory files in Canada, Australia, and Mexico, demonstrating its capability to implement its innovative product pipeline [6]. Group 3: Strategic Focus and Future Events - Viatris is expected to prioritize the global rollout of its products leading up to a significant Investor Event on March 19, 2026, coinciding with the release of its fourth-quarter and full-year 2025 results on February 26, 2026 [6].

Financial Data and Key Metrics Changes - Total revenue for 2025 grew by 38% to $1.4 billion, with royalty revenue increasing by 52% to $868 million, reflecting strong performance from ENHANZE-enabled products [9][17] - Net income for the full year was $316.9 million, down from $444.1 million in 2024, impacted by a $285 million acquired IP R&D expense [19] - Adjusted EBITDA was $657.6 million, compared to $632.2 million in 2024, indicating operational strength despite the IP charge [19] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10] - PHESGO's royalty revenue increased by 51% to $105.6 million, with total sales growing 48% year-over-year to approximately $3 billion [11] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12] Market Data and Key Metrics Changes - ENHANZE now has 10 global blockbuster opportunities, with significant approvals in the U.S., Japan, and China for various products [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13] Company Strategy and Development Direction - The company aims to expand its ENHANZE pipeline, projecting 6 new programs to enter phase one in 2026, bringing the total development portfolio to 15 products [24] - The strategy includes pursuing additional licensing agreements and evaluating new drug delivery technologies to enhance long-term revenue streams [27][28] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, emphasizing the durability of royalty revenue and the potential for exceptional value creation [23] - The company anticipates continued strong growth driven by existing products and new collaborations, with a focus on expanding into new therapeutic areas [25][36] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities and extending IP into the mid-2040s [6][27] - The balance sheet was strengthened with the issuance of convertible notes and an upsized revolving credit facility, reducing near-term refinancing risk [21] Q&A Session Summary Question: Regarding the DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42] Question: On the ADC strategy and regulatory paths - The regulatory pathway for converting ADCs from IV to subcutaneous is expected to follow traditional PK non-inferiority studies, with additional trials for unapproved products [50] Question: Update on Hypercon products and clinical testing - Two Hypercon products are on track for phase 1 clinical testing in 2026, with completion of clinical scale-up batches and IND filings underway [66] Question: Potential incremental royalty opportunities from Merus's petosemtamab - Management highlighted the potential for expanded indications and the importance of subcutaneous formulations in enhancing patient treatment experiences [58]

Financial Data and Key Metrics Changes - Total revenue grew 38% to $1.4 billion, with royalty revenue increasing 52% to $868 million for the full year 2025 [9][17][19] - Net income for the full year was $316.9 million, compared to $444.1 million in 2024, while adjusted EBITDA was $657.6 million, up from $632.2 million in 2024 [19][20] - GAAP diluted EPS was $2.50, down from $3.43 in 2024, while non-GAAP diluted EPS was $4.15, compared to $4.23 in 2024 [19][20] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10][19] - Phesgo's royalty revenue increased 51% year-over-year to $105.6 million, with total sales growing 48% to approximately $3 billion [11][19] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12][19] Market Data and Key Metrics Changes - ENHANZE-enabled products now include 10 global blockbuster opportunities, with significant approvals in multiple markets including the U.S., Japan, and China [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13][16] Company Strategy and Development Direction - The company aims to expand its ENHANZE portfolio with six new programs entering phase I in 2026, bringing the total development portfolio to 15 products [24][35] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26][27] - The company plans to pursue strategic acquisitions to enhance its drug delivery portfolio while maintaining financial discipline [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, highlighting multiple revenue drivers and the durability of royalty revenue [23][39] - The company anticipates continued strong growth from existing products and new launches, with a focus on expanding into new therapeutic areas [24][35] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities with long-duration IP [6][27] - The company expects to maintain a strong balance sheet and reduce net debt to below 1x by the end of 2026 [21][22] Q&A Session Summary Question: Regarding the mechanics of DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42][43] Question: On the ADC strategy and regulatory paths - Management indicated that the regulatory pathway for converting IV to subcutaneous delivery would likely follow traditional PK non-inferiority studies [49][50] Question: Update on Hypercon products and clinical testing - Management confirmed that two Hypercon products are on track for phase I clinical testing in 2026, with completion of clinical scale-up batches underway [63][64] Question: Expectations for new partnerships in auto-injectors - Management anticipates progress with high-volume auto-injectors and expects to see interest from both current and new partners [75][76]

Financial Data and Key Metrics Changes - Total revenue grew 38% to $1.4 billion, with royalty revenue increasing 52% to $868 million for the full year 2025 [7][15][17] - Net income for the full year was $316.9 million, compared to $444.1 million reported in 2024 [17] - Adjusted EBITDA was $657.6 million, compared to $632.2 million in 2024 [17] - GAAP diluted EPS was $2.50, compared with $3.43 in 2024, while non-GAAP diluted EPS was $4.15, compared with $4.23 in 2024 [17][18] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenues, representing 29% year-over-year growth, with total sales growing 22% to $14.4 billion [8][9] - PHESGO delivered $105.6 million in royalty revenue, reflecting 51% year-over-year growth, with total sales increasing 48% to approximately $3 billion [9][10] - VYVGART and VYVGART Hytrulo generated $157.2 million in royalty revenue, representing 444% year-over-year growth, with total sales growing 90% to $4.15 billion [10][11] Market Data and Key Metrics Changes - The company now has 10 ENHANZE-enabled global blockbuster opportunities, with significant approvals in the U.S., Japan, and China [6][12] - Roche reported that there are now 17,500 patients on Ocrevus Zunovo, a 5,000 patient increase from the third quarter [11] - Analysts project that PHESGO will reach CHF 3.6 billion in 2028, and Ocrevus franchise sales expectations have been increased to CHF 9 billion, or approximately $11.5 billion [10][12] Company Strategy and Development Direction - The company expanded its portfolio from two to four subcutaneous drug delivery technologies through acquisitions, positioning itself as a one-stop shop for biopharma subcutaneous drug delivery [5][6] - The focus is on advancing the ENHANZE pipeline, with projections for 6 new ENHANZE programs entering phase one in 2026 [21][32] - The company aims to continue strategic M&A to enhance its drug delivery portfolio and maintain financial discipline while investing in long-term value creation [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, highlighting multiple revenue drivers that will support durable royalty revenue [20][36] - The company anticipates continued strong growth from its existing blockbusters and new product launches, with a focus on expanding into new therapeutic areas [20][21] - Management expects to enter discussions with Johnson & Johnson to extend the DARZALEX collaboration agreement closer to its expiration in 2032 [39][40] Other Important Information - The company signed three new ENHANZE collaboration and licensing agreements, expanding its reach beyond oncology into obesity and inflammatory bowel disease [6][7] - The acquisition of Surf Bio is expected to enhance the company's hyperconcentration technology capabilities [24] - The company ended the year with a net debt to EBITDA ratio of 2.1x, with expectations to deleverage to below 1x by the end of 2026 [19] Q&A Session Summary Question: Can you elaborate on the mechanics of the DARZALEX collaboration with J&J? - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, as they do not anticipate J&J seeking another source of API [39][40] Question: What are the regulatory paths for ADCs with ENHANZE? - The regulatory pathway for converting from IV to subcutaneous is expected to follow traditional PK non-inferiority studies, while additional benefits would require phase trials [46][47] Question: What is the progress on Hypercon products? - The company is on track to support two partners in advancing to phase 1 clinical testing in 2026, with clinical scale-up batches being completed [61][62] Question: How will sales from auto-injectors be reported? - Sales from auto-injectors will be recognized similarly to API sales, with royalties recognized on commercial sales [76]

Core Insights - The iShares S&P Mid-Cap 400 Value ETF (IJJ) focuses on mid-cap U.S. companies, while the iShares Morningstar Small-Cap Value ETF (ISCV) targets a broader small-cap universe [1][2] Cost & Size Comparison - ISCV has a lower expense ratio of 0.06% compared to IJJ's 0.18% [3][4] - As of February 4, 2026, ISCV's one-year return is 13.3%, while IJJ's is 9.8% [3] - ISCV offers a higher dividend yield of 1.9% compared to IJJ's 1.7% [3][4] - ISCV has assets under management (AUM) of $609.2 million, whereas IJJ has $8.3 billion [3] Performance & Risk Comparison - Over the past five years, ISCV experienced a maximum drawdown of -25.35%, while IJJ had a drawdown of -22.68% [5] - An investment of $1,000 would have grown to $1,452 in ISCV and $1,528 in IJJ over five years [5] Portfolio Composition - IJJ holds 305 stocks, with significant allocations in Financial Services (25%), Industrials (17%), and Consumer Cyclical (14%) [6] - Top holdings in IJJ include US Foods Holding Corp., Reliance Steel & Aluminum, and Alcoa Corp. [6] - ISCV has a larger portfolio with 1,083 holdings, focusing on Financial Services (21%), Consumer Cyclical (15%), and Industrials (13%) [7] - Leading positions in ISCV are Viatris Inc., Alcoa Corp., and Annaly Capital Management REIT Inc. [7] Investment Implications - The choice between IJJ and ISCV depends on individual investment goals, with ISCV being more suitable for aggressive investors seeking high growth due to its higher return and better dividend yield [8]

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as a promising healthcare stock priced under $50, with a recent price target adjustment from Piper Sandler to $12 from $9 while maintaining a Neutral rating, indicating confidence in the brand's performance across various geographies and potential steady contributions from new product launches [1] Product Launch and Strategy - On January 20, Viatris announced the launch of Inpefa® (sotagliflozin) in the UAE, marking it as the first country within its territories to commercialize this treatment, with plans for future launches in several countries to enhance treatment access in key markets outside Europe and the U.S. [2] - Inpefa is the first and only dual SGLT1/2 inhibitor approved for treating heart failure, with approvals in the UAE and the U.S. to reduce hospitalization risks for heart failure and cardiovascular-related issues in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors [3] Company Overview - Viatris is a global healthcare company offering a wide range of healthcare and pharmaceutical products across various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women's healthcare. Its operations are segmented into Developed Markets, Greater China, JANZ, and Emerging Markets [4]